Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Key Stats

• Today's Range: $590.15 to $606.00
• 50-Day Range: $527.78 to $661.00
• 52-Week Range: $520.50 to $1,211.20
• Volume: 1.01 million shs
• Average Volume: 801,172 shs
• Market Capitalization: $63.90 billion
• P/E Ratio: 15.46
• Dividend Yield: 0.59%
• Price Target: $890.60
• Consensus Rating: Moderate Buy

Regeneron Pharmaceuticals Stock Analysis - MarketRank™

Regeneron Pharmaceuticals scored higher than 98% of companies evaluated by MarketBeat, and ranked 40th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Regeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 19 buy ratings, 3 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Regeneron Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.85%

Earnings Growth

Earnings for Regeneron Pharmaceuticals are expected to grow by 5.85% in the coming year, from $35.92 to $38.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Regeneron Pharmaceuticals is 15.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.46.

Price to Earnings Ratio vs. Sector

The P/E ratio of Regeneron Pharmaceuticals is 15.46, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.90.

Price to Earnings Growth Ratio

Regeneron Pharmaceuticals has a PEG Ratio of 2.34. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Regeneron Pharmaceuticals has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.69% of the float of Regeneron Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regeneron Pharmaceuticals has recently decreased by 3.11%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Regeneron Pharmaceuticals has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Regeneron Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Regeneron Pharmaceuticals is 8.96%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 9.26% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 2.3 / 5
• Environmental Score: -2.69

Percentage of Shares Shorted

2.69% of the float of Regeneron Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regeneron Pharmaceuticals has recently decreased by 3.11%, indicating that investor sentiment is improving.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.22

News Sentiment

Regeneron Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for Regeneron Pharmaceuticals this week, compared to 30 articles on an average week.

Search Interest

38 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

12 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Regeneron Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.02% of the stock of Regeneron Pharmaceuticals is held by insiders.

Percentage Held by Institutions

83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

REGN Stock Analysis - Frequently Asked Questions

How have REGN shares performed this year?

Regeneron Pharmaceuticals' stock was trading at $712.33 at the beginning of 2025. Since then, REGN stock has decreased by 16.9% and is now trading at $591.85.
View the best growth stocks for 2025 here.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Tuesday, April, 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by $0.61. Regeneron Pharmaceuticals's revenue was down 3.7% compared to the same quarter last year.
Read the conference call transcript.

Does Regeneron Pharmaceuticals have any subsidiaries?

Regeneron Pharmaceuticals subsidiaries include Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more.

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' top institutional investors include Vanguard Group Inc. (8.61%), Dodge & Cox (2.13%), Price T Rowe Associates Inc. MD (1.99%) and Amundi (1.47%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi and N Anthony Coles.
View institutional ownership trends.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Record date for 3/20 Dividend: 2/20/2025
• Ex-Dividend for 3/20 Dividend: 2/20/2025
• Dividend Payable: 3/20/2025
• Last Earnings: 4/29/2025
• Record date for 6/6 Dividend: 5/20/2025
• Ex-Dividend for 6/6 Dividend: 5/20/2025
• Today: 5/28/2025
• Dividend Payable: 6/06/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:REGN
• CIK: 872589
• Web: www.regeneron.com
• Phone: (914) 847-7000
• Fax: 914-347-2113
• Employees: 11,900
• Year Founded: 1988

Price Target and Rating

• Average Stock Price Target: $890.60
• High Stock Price Target: $1,200.00
• Low Stock Price Target: $150.00
• Potential Upside/Downside: +50.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 26 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $39.28
• Trailing P/E Ratio: 15.46
• Forward P/E Ratio: 16.48
• P/E Growth: 2.34
• Net Income: $4.41 billion
• Net Margins: 31.07%
• Pretax Margin: 33.66%
• Return on Equity: 16.32%
• Return on Assets: 12.76%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 4.73
• Quick Ratio: 3.95

Sales & Book Value

• Annual Sales: $14.09 billion
• Price / Sales: 4.54
• Cash Flow: $38.86 per share
• Price / Cash Flow: 15.23
• Book Value: $268.50 per share
• Price / Book: 2.20

Miscellaneous

• Outstanding Shares: 107,965,000
• Free Float: 101,147,000
• Market Cap: $63.90 billion
• Optionable: Optionable
• Beta: 0.43